Article · 29 Dec 2025
Conference abstractPublished 24 Oct 2018
Process development with Chinese Hamster Ovary and hybridoma cell lines: Differences, challenges, things to know
Invenux LLC Windsor, US
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
When utilizing different cell lines, expression, productivity and upstream process design, in general, need to be adapted to the metabolism and behavior of these cells. In the upstream process, critical to achieving high biosimilar yields are the choice of the expression system and cell line. For biosimilars, this a rapidly changing landscape as biosimilar manufacturers are no longer bound by technologies used decades ago to produce the original biologic. This Workshop will discuss these choices for Chinese Hamster Ovary (CHO) and Hybridoma cell lines.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Robert Swift”

